Quetiapine: Difference between revisions
Notjusttired (talk | contribs) (stub) |
Notjusttired (talk | contribs) m (Text replacement - " | first" to " | first") |
||
(112 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
'''Quetiapine''' is an atypical | '''Quetiapine''', also known under the brand name '''Seroquel''', is an atypical antipsychotic drug which is sometimes used off-label at lower doses to treat [[insomnia]].<ref name="drugscom">{{Cite web|url=https://www.drugs.com/seroquel.html | title = Seroquel: Drug Uses, Dosage & Side Effects|website=Drugs.com|language=en|access-date=2021-03-09}}</ref><ref name="FibroQandA" /><ref name="Wilson2019" /> Quetiapine is also a [[dopamine]] [[serotonin]] antagonist.<ref name="Wilson2019">{{Cite journal | last = Wilson | first = Sue | last2 = Anderson | first2 = Kirstie | last3 = Baldwin | first3 = David | last4 = Dijk | first4 = Derk-Jan | last5 = Espie | first5 = Audrey | last6 = Espie | first6 = Colin | last7 = Gringras | first7 = Paul | last8 = Krystal | first8 = Andrew | last9 = Nutt | first9 = David | date = 2019-07-04 | title = British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update|url=https://www.dx.org/10.1177/0269881119855343|journal=Journal of Psychopharmacology|volume=33|issue=8 | pages = 923–947|doi=10.1177/0269881119855343|issn=0269-8811}}</ref>{{Rp|934}} | ||
Quetiapine may be used for Schizophrenia, Bipolar disorder (manic depression), or, when combined with an [[antidepressant]], to treat [[depression]].<ref name="drugscom" /> | |||
==ME/CFS and Fibromyalgia== | |||
It is a sedating drug sometimes used for ''off-label'' for insomnia, including in patients with [[Fibromyalgia]].<ref name="FibroQandA">{{Cite book | title = 100 Questions & Answers About Fibromyalgia | pages = 80|isbn=978-0-7637-8708-0|edition=|volume=|language=en|title-link=|url=https://books.google.co.uk/books?id=dA4kQulQ2ZMC&lpg=PP1&vq=quetiapine&pg=PT80#v=onepage&q=insomnia&f=false|access-date= | date = 2009-05-05|publisher=Jones & Bartlett Publishers | last = Ostalecki | first = Sharon | author-link = | last2 = Tamler | first2 = Martin S. | authorlink2 = |veditors=|others=|doi=|oclc=|quote=|archive-url=|archive-date=|location= | editor-last = | editor-first = |editor1-link=|editor-last2=|editor-first2 = }}</ref>{{Rp|80}} <ref name="Wilson2019" /> | |||
==Theory== | ==Theory== | ||
==Evidence== | ==Evidence== | ||
There are no clinical trials for the use of quetiapine in patients with chronic fatigue syndrome or fibromyalgia. There have been several small clinical trials of 25mg of quetiapine in patients with insomnia, with mixed results.<ref name="Wilson2019" /> | |||
The [[International Consensus Criteria]] primer advises against the use of quetiapine in overweight patients with [[myalgic encephalomyelitis]].<ref name="ICP2011primer">{{citation | last1 = Carruthers | first1 = BM | authorlink1 = Bruce Carruthers | last2 = van de Sande | first2 = MI | authorlink2 = Marjorie van de Sande | last3 = De Meirleir | first3 = KL | authorlink3 = Kenny de Meirleir | last4 = Klimas | first4 = NG | authorlink4 = Nancy Klimas | last5 = Broderick | first5 = G | authorlink5 = Gordon Broderick | last6 = Mitchell | first6 = T | authorlink6 = Terry Mitchell | last7 = Staines | first7 = D | authorlink7 = Donald Staines | last8 = Powles | first8 = ACP | authorlink8 = A C Peter Powles | last9 = Speight | first9 = N | authorlink9 = Nigel Speight | last10 = Vallings | first10 = R | authorlink10 = Rosamund Vallings | last11 = Bateman | first11 = L | authorlink11 = Lucinda Bateman | last12 = Bell | first12 = DS | authorlink12 = David Bell | last13 = Carlo-Stella | first13 = N | authorlink13 = Nicoletta Carlo-Stella | last14 = Chia | first14 = J | authorlink14 = John Chia | last15 = Darragh | first15 = A | authorlink15 = Austin Darragh | last16 = Gerken | first16 = A | authorlink16 = Anne Gerken | last17 = Jo | first17 = D | authorlink17 = Daehyun Jo | last18 = Lewis | first18 = DP | authorlink18 = Donald Lewis | last19 = Light | first19 = AR | authorlink19 = Alan Light | last20 = Light | first20 = KC | authorlink20 = Kathleen Light | last21 = Marshall-Gradisnik | first21 = S | authorlink21 = Sonya Marshall-Gradisnik | last22 = McLaren-Howard | first22 = J | authorlink22 = John McLaren-Howard | last23 = Mena | first23 = I | authorlink23 = Ismael Mena | last24 = Miwa | first24 = K | authorlink24 = Kunihisa Miwa | last25 = Murovska | first25 = M | authorlink25= Modra Murovska | last26 = Stevens | first26 = SR | authorlink26 = Staci Stevens | title = Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners | date = 2012 | |||
| isbn = 978-0-9739335-3-6 | url = http://www.investinme.org/Documents/Guidelines/Myalgic%20Encephalomyelitis%20International%20Consensus%20Primer%20-2012-11-26.pdf }}</ref>{{Rp|13}} | |||
==Risks and safety== | ==Risks and safety== | ||
==Costs and availability== | ==Costs and availability== | ||
==Notable studies == | |||
* 2012, The role of Antipsychotics in the Management of Fibromyalgia<ref name="Calandre2012">{{Cite journal | last = Calandre | first = Elena P. | last2 = Rico-Villademoros | first2 = Fernando | date = 2012-02-01 | title = The Role of Antipsychotics in the Management of Fibromyalgia|url=https://doi.org/10.2165/11597130-000000000-00000|journal=CNS Drugs|language=en|volume=26|issue=2|pages=135–153|doi=10.2165/11597130-000000000-00000|issn=1179-1934}}</ref> - [https://link.springer.com/article/10.2165/11597130-000000000-00000 (Abstract)] | |||
==See also== | ==See also== | ||
*[[Fibromyalgia]] | |||
*[[Fibromyalgia drugs]] | |||
*[[Myalgic encephalomyelitis]] | |||
==Learn more== | ==Learn more== | ||
*[https://www.bap.org.uk/pdfs/BAP_Guidelines-Sleep.pdf British Association for Psychopharmacology consensus statement on evldence-based treatment of insomnia, parasomnias and cicadian rhythm disorders: An update] | |||
* | |||
==References== | ==References== | ||
Line 51: | Line 33: | ||
[[Category:Antipsychotics]] | [[Category:Antipsychotics]] | ||
[[Category:Sleep aids and hypnotics]] | |||
[[Category:Potential treatments]] | [[Category:Potential treatments]] |
Latest revision as of 16:34, April 3, 2023
Quetiapine, also known under the brand name Seroquel, is an atypical antipsychotic drug which is sometimes used off-label at lower doses to treat insomnia.[1][2][3] Quetiapine is also a dopamine serotonin antagonist.[3]:934
Quetiapine may be used for Schizophrenia, Bipolar disorder (manic depression), or, when combined with an antidepressant, to treat depression.[1]
ME/CFS and Fibromyalgia[edit | edit source]
It is a sedating drug sometimes used for off-label for insomnia, including in patients with Fibromyalgia.[2]:80 [3]
Theory[edit | edit source]
Evidence[edit | edit source]
There are no clinical trials for the use of quetiapine in patients with chronic fatigue syndrome or fibromyalgia. There have been several small clinical trials of 25mg of quetiapine in patients with insomnia, with mixed results.[3]
The International Consensus Criteria primer advises against the use of quetiapine in overweight patients with myalgic encephalomyelitis.[4]:13
Risks and safety[edit | edit source]
Costs and availability[edit | edit source]
Notable studies[edit | edit source]
- 2012, The role of Antipsychotics in the Management of Fibromyalgia[5] - (Abstract)
See also[edit | edit source]
Learn more[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 "Seroquel: Drug Uses, Dosage & Side Effects". Drugs.com. Retrieved March 9, 2021.
- ↑ 2.0 2.1 Ostalecki, Sharon; Tamler, Martin S. (May 5, 2009). 100 Questions & Answers About Fibromyalgia. Jones & Bartlett Publishers. p. 80. ISBN 978-0-7637-8708-0.
- ↑ 3.0 3.1 3.2 3.3 Wilson, Sue; Anderson, Kirstie; Baldwin, David; Dijk, Derk-Jan; Espie, Audrey; Espie, Colin; Gringras, Paul; Krystal, Andrew; Nutt, David (July 4, 2019). "British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update". Journal of Psychopharmacology. 33 (8): 923–947. doi:10.1177/0269881119855343. ISSN 0269-8811.
- ↑ Carruthers, BM; van de Sande, MI; De Meirleir, KL; Klimas, NG; Broderick, G; Mitchell, T; Staines, D; Powles, ACP; Speight, N; Vallings, R; Bateman, L; Bell, DS; Carlo-Stella, N; Chia, J; Darragh, A; Gerken, A; Jo, D; Lewis, DP; Light, AR; Light, KC; Marshall-Gradisnik, S; McLaren-Howard, J; Mena, I; Miwa, K; Murovska, M; Stevens, SR (2012), Myalgic encephalomyelitis: Adult & Paediatric: International Consensus Primer for Medical Practitioners (PDF), ISBN 978-0-9739335-3-6
- ↑ Calandre, Elena P.; Rico-Villademoros, Fernando (February 1, 2012). "The Role of Antipsychotics in the Management of Fibromyalgia". CNS Drugs. 26 (2): 135–153. doi:10.2165/11597130-000000000-00000. ISSN 1179-1934.